Pharma Right Group

pharmarightgroup.com

Pharma Right Group is a cluster of 3 leading pharmaceutical companies (Pharma Right, RAI Pharmaceuticals, and Empire Pharma), with a diversified & integrated portfolio in pharmaceutical business Pharma Right Group has a believe& primary focus to be a healthcare provider in Egypt ,North Africa and Middle East region with innovative, high quality, and affordable healthcare products in different therapeutic areas like G.I.T, Anti-Infectives ,Cosmoceuticals and Neuroscience. We have the passion to think differently to do right things & drive up community health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

AIKIDO PHARMA ANNOUNCES STRATEGIC INVESTMENT IN SOCIAL COMMUNICATIONS PLATFORM PROVIDER DISCORD, INC

AIkido Pharma Inc. | May 05, 2022

news image

AIkido Pharma Inc. announced that the Company has secured an early equity interest in privately-held Discord, Inc. a social communications platform provider that is particularly popular with gamers. Bloomberg Technology reported on March 14, 2022, that Discord "is interviewing bankers about going public as soon as this year." According to the Bloomberg report, "Discord, last valued by private investors at about $15 billion, is especially popular with gamers and youn...

Read More

OPTUM DRIVES UNITEDHEALTH’S BETTER-THAN-EXPECTED EARNINGS

MedCity News - | January 16, 2020

news image

In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Optum segment reporting double-digit growth across the board. The company also managed to grow its already large presence in the Medicare Advantage market, despite several new competitors. Overall, Unite...

Read More

BUSINESS INSIGHTS

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

news image

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More

BUSINESS INSIGHTS

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More
news image

BUSINESS INSIGHTS

AIKIDO PHARMA ANNOUNCES STRATEGIC INVESTMENT IN SOCIAL COMMUNICATIONS PLATFORM PROVIDER DISCORD, INC

AIkido Pharma Inc. | May 05, 2022

AIkido Pharma Inc. announced that the Company has secured an early equity interest in privately-held Discord, Inc. a social communications platform provider that is particularly popular with gamers. Bloomberg Technology reported on March 14, 2022, that Discord "is interviewing bankers about going public as soon as this year." According to the Bloomberg report, "Discord, last valued by private investors at about $15 billion, is especially popular with gamers and youn...

Read More
news image

OPTUM DRIVES UNITEDHEALTH’S BETTER-THAN-EXPECTED EARNINGS

MedCity News - | January 16, 2020

In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Optum segment reporting double-digit growth across the board. The company also managed to grow its already large presence in the Medicare Advantage market, despite several new competitors. Overall, Unite...

Read More
news image

BUSINESS INSIGHTS

SANDOZ TARGETS GROWTH OPPORTUNITIES IN RESPIRATORY AND COMPLEX GENERICS THROUGH ACQUISITION OF RESPIRATORY DEVICE COMPANY COALESCE

Novartis Pharma AG | March 14, 2022

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Read More
news image

BUSINESS INSIGHTS

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More